Autism Speaks and the Autism Clinical Trials Network report that a new low dose, melt-in-your-mouth version of Fluoxetine failed to reduce repetitive behaviors in children and adolescents diagnosed with Autism. Physicians' clinical observations that Fluoxetine controlled these behaviors spurred this research. Fluoxetine is selective serotonin reuptake inhibitor (SSRI) that is commonly referred to as a "anti ...

I am very pleased to provide the response of our first invited guest commentator, Mirjam Kouijzer, lead author of the research discussed in the recent BMED Report article, Neurofeedback For Autistic Spectrum Disorders: Promising Results In A Small Sample.  The BMED Report extends a warm thanks to Mirjam Kouijzer and Hein van Schie for this response. Mirjam Kouijzer’s Response: Investigating effects of neuro ...

This current report extends the initial findings of  “Neurofeedback For Autistic Spectrum Disorders: Promising Results In A Small Sample” to a 1 year follow-up of the same participants with Autism Spectrum Disorders (ASD).  Recall from the initial study that participants with ASD experienced statistically meaningful improvements in a variety of executive functioning, social, and behavioral areas following 4 ...

Autistic Spectrum Disorders (ASD) are characterized by significant deficits in social skills, attention/concentration, and communication, as well as emotional, cognitive, and behavioral impairments. Examples include Autism, Asperger's Disorder, and Pervasive Developmental Disorder Not Otherwise Specified. I am not aware of any treatment that can "cure" ASD. Current therapies focus on symptom reduction, beha ...